Dislocation

Dislocation

Molina fell 66% from a September 2024 peak of $360.77 to a February 2026 trough of $122.65, a 513-day, multi-leg decline. The cause is identifiable and dated: four 2025 cuts to full-year adjusted EPS guidance — $24.50 to roughly $10.65 — driven by medical-cost inflation across Medicaid, Medicare and the ACA Marketplace. Volume spiked to 5.57x its pre-peak median. Revenue never faltered; margin did.

The drawdown, quantified

Source: derived from daily price data; drawdown figures per the deterministic capitulation gauge (fit_features.capitulation_gauge.drawdown).

Source: daily market data, as reported; peak/trough anchors per fit_features.capitulation_gauge.

The fall runs in two distinct phases. From the September 2024 peak of $360.77 the stock drifted to about $306 by July 1, 2025 — a 15% slide over nine and a half months, on ordinary volume and with no single dated event. That is drift, not the moment. The moment began on July 2, 2025, when the shares dropped 22% in one session, and the capitulation from there to the February 2026 trough was roughly 60%. (Molina traded higher still — $419.53 — in March 2024; the gauge anchors the capitulation leg at the September-2024 local peak.)

The triggers — four dated guidance cuts

Every leg of the capitulation lines up with a dated document lowering full-year 2025 adjusted EPS. Revenue beat consensus in each of those quarters; the cuts were about medical costs.

Sources: Q2 FY2025 earnings call [1]; Q3 FY2025 call [2]; Q4 FY2025 call [3]; Q1 FY2026 call [4]; price and volume from daily market data.

The single largest one-day fall, July 2, 2025 (down 22%), was not Molina-specific news but sector contagion: Centene withdrew its own 2025 guidance the prior evening, and the managed-care group repriced together [5]. Molina supplied its own trigger five days later, on July 7, 2025, pre-announcing preliminary Q2 results and cutting FY2025 EPS guidance to a $21.50–$22.50 range. At the formal Q2 call on July 24, management cut again, to "no less than $19 per share… which is $5.50 below our initial guidance of $24.50 and $3 lower than the midpoint of what was recently communicated on July 7" [6].

The mechanism is a medical-cost trend that outran the rates Molina is paid. Management called it plainly: "The magnitude and persistence of these medical cost increases are unprecedented" [7]. The third cut arrived with Q3 on October 23, 2025 — full-year adjusted EPS "now expected to be approximately $14 per share, which is $5 below our prior guidance of $19" [8] — as the Marketplace medical care ratio hit 95.6%, meaning the segment paid out 95.6 cents of medical claims on every premium dollar [9]. The year ended below even that: a Q4 "adjusted loss per share of $2.75" reported February 5, 2026 [10], pinning the trough on February 11 at $122.65. The strain is visible in the audited full year: the Medicaid MCR "increased 150 basis points to 91.8% in 2025, compared to 90.3% in 2024" [11].

Source: Q2 FY2025 call (initial $24.50, July 7 midpoint, $19 floor) [12]; Q3 FY2025 call ($14) [13]; FY25 actual is the sum of reported quarterly adjusted EPS ($6.08 + $5.48 + $1.84 − $2.75).

The fear gauge

The capitulation gauge measures the heaviest 20-day average volume in the peak-to-trough leg against the median daily volume of the 180 days before the peak. That ratio is 5.57x (fit_features.capitulation_gauge.volume_spike). The heaviest sustained volume came early, in the July 2025 leg — the first guidance shock, not the final one — while the single heaviest session was February 6, 2026, at 10.3 million shares against a pre-peak median near 0.41 million, roughly 25x a normal day. Volume of that size, clustered on the guidance-cut dates rather than spread through the drift, is the signature of emotion-driven selling rather than orderly repricing.

Who was selling

The seller identity is only partly observable. Official reported short interest is unavailable for this run — FINRA returned no position rows — so short-interest level and change cannot be quantified here. What the records do show argues against forced or informed insider distribution:

Insider Form 4 activity through the fall is grants and tax-withholding, not open-market selling. The one open-market insider sale on file, the Chief Legal Officer's 17,811 shares at $186.12 (about $3.3 million), came on May 11, 2026 — during the recovery, well above the trough, not into the decline. Molina remained in the S&P 500 across the drawdown, so there was no index-deletion forced selling. The most economical reading of the tape is broad institutional repricing coincident with the whole managed-care group, which cut guidance in the same window (Centene, UnitedHealth, Elevance), rather than a single identifiable forced seller.

Estimates versus price

This is where the framework's usual signature is absent. A dislocation worth acting on often shows price falling faster than estimates — fear compressing the multiple on largely unchanged numbers. Molina is the opposite case: revenue estimates barely moved while earnings estimates collapsed in step with the guidance, and price tracked the earnings down rather than outrunning it.

Source: CapIQ consensus momentum snapshots (fit_features.consensus_forward_yield context, data/sp/estimates.json); price from daily market data.

Consensus FY2027 revenue held in a $47–50 billion band throughout; demand for Molina's government-program business was never the question. FY2027 adjusted EPS, by contrast, was nearly halved — from $16.34 in January 2026 to $8.54 by April — across the same window that carried the February trough. Measured peak-to-trough, price fell 66% while initial FY2025 EPS guidance fell 57% ($24.50 to a $10.65 actual); the de-rating largely tracked a real, dated earnings reset, not a multiple compressed by fear alone.

The overshoot evidence sits at the low, not in the down-leg: the trough was set by a 25% single-day capitulation on the Q4 loss, and the stock has since recovered 83% — to $224.82 from $122.65 — while forward EPS estimates barely recovered (FY2027 from $8.54 to $9.29). The re-rating off the bottom outran the estimate change, which is where fear, rather than fundamentals, did the extra work. Whether the earnings reset is temporary or permanent — and what it does to value — belongs to the Damage Math, not here. This tab establishes only what happened: a genuine, severe, dated dislocation whose down-leg was earnings-driven and whose trough carried the marks of capitulation.